$567.44 Million in Sales Expected for Amedisys, Inc. (NASDAQ:AMED) This Quarter

Equities analysts predict that Amedisys, Inc. (NASDAQ:AMED) will post $567.44 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $562.17 million and the highest is $574.88 million. Amedisys reported sales of $544.07 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.3%. The business is scheduled to issue its next earnings results on Wednesday, October 27th.

On average, analysts expect that Amedisys will report full year sales of $2.25 billion for the current financial year, with estimates ranging from $2.23 billion to $2.26 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $2.47 billion, with estimates ranging from $2.43 billion to $2.51 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Amedisys.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, August 4th. The health services provider reported $1.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.02. Amedisys had a net margin of 11.25% and a return on equity of 28.55%. The firm had revenue of $564.17 million for the quarter, compared to analyst estimates of $565.48 million. During the same quarter last year, the firm posted $1.34 earnings per share. Amedisys’s revenue for the quarter was up 16.3% compared to the same quarter last year.

A number of analysts have recently issued reports on AMED shares. Benchmark dropped their price objective on shares of Amedisys from $325.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, August 10th. Raymond James dropped their price objective on shares of Amedisys from $325.00 to $250.00 and set an “outperform” rating on the stock in a research note on Monday, August 9th. Credit Suisse Group dropped their price objective on shares of Amedisys from $330.00 to $250.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 11th. Stephens dropped their price objective on shares of Amedisys from $310.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, August 6th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered shares of Amedisys from a “buy” rating to a “hold” rating and set a $273.00 price objective on the stock. in a research note on Tuesday, June 15th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $269.83.

In other news, COO Christopher Gerard sold 1,250 shares of the business’s stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $261.24, for a total transaction of $326,550.00. Following the completion of the transaction, the chief operating officer now owns 39,006 shares of the company’s stock, valued at $10,189,927.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bruce D. Perkins sold 11,511 shares of the business’s stock in a transaction on Wednesday, September 1st. The shares were sold at an average price of $183.00, for a total transaction of $2,106,513.00. Following the transaction, the director now directly owns 29,380 shares of the company’s stock, valued at approximately $5,376,540. The disclosure for this sale can be found here. Insiders own 1.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Amedisys during the second quarter valued at $72,000. Eubel Brady & Suttman Asset Management Inc. acquired a new position in shares of Amedisys during the second quarter valued at $26,000. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Amedisys by 55.0% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 169 shares of the health services provider’s stock valued at $45,000 after acquiring an additional 60 shares during the period. Van ECK Associates Corp bought a new stake in shares of Amedisys during the first quarter valued at about $48,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Amedisys by 38.0% during the first quarter. First Horizon Advisors Inc. now owns 247 shares of the health services provider’s stock valued at $65,000 after purchasing an additional 68 shares in the last quarter. 87.35% of the stock is owned by institutional investors.

AMED opened at $169.02 on Friday. The firm has a market capitalization of $5.52 billion, a P/E ratio of 22.69, a P/E/G ratio of 2.69 and a beta of 0.51. The firm’s 50 day moving average is $211.23 and its 200-day moving average is $244.56. Amedisys has a 52-week low of $166.01 and a 52-week high of $325.12. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 0.20.

Amedisys declared that its board has approved a share repurchase program on Wednesday, August 4th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the health services provider to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Amedisys Company Profile

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.

Featured Story: What does it mean to hold a stock in street name?

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.